Ignite Creation Date:
2025-12-24 @ 4:48 PM
Ignite Modification Date:
2026-01-06 @ 6:25 PM
Study NCT ID:
NCT02306850
Status:
COMPLETED
Last Update Posted:
2019-06-20
First Post:
2014-12-01
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Sponsor:
St. Louis University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-01
Start Date Type:
None
Primary Completion Date:
2018-06-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-06-08
Completion Date Type:
ACTUAL
First Submit Date:
2014-12-01
First Submit QC Date:
None
Study First Post Date:
2014-12-03
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-06-03
Results First Submit QC Date:
None
Results First Post Date:
2019-06-20
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-06-03
Last Update Post Date:
2019-06-20
Last Update Post Date Type:
ACTUAL